Midatech is commercialising oncology treatment and supportive care products through its US commercial organisation, Midatech Pharma US (“Midatech US”) (formerly DARA BioSciences, Inc.). In Europe, Midatech is developing a pipeline of product candidates in clinical and pre-clinical development for diseases for which there are currently few or no treatment options available. These diseases include rare cancers including brain (glioblastoma, DIPG), and liver cancer.Midatech’s strategy is to expand its US commercial arm as well as develop its products in-house in orphan oncology and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.All of Midatech’s product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery (‘right place’) and controlled release (‘right time’) of existing drugs.
|Bank Name||Midatech Pharma PLC|
|CEO||Dr. Craig Richard Cook|